ASCO GU 2019 - Results from #80

Viewing 81-100 of 154 articles

ASCO GU 2019: TALAPRO-2: A Two-Part, Placebo-Controlled Phase III Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2019: Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma - An Analysis of Overall Survival

ASCO GU 2019: Metastatic Seminomas Show Expression of Immune Related Pathways

ASCO GU 2019: Penile Squamous Cell Carcinoma is Genomically Similar to Other HPV-Driven Tumors

ASCO GU 2019: Point-Counterpoint: Subgroup Analyses Can Be Used to Change Clinical Practice Guidelines

ASCO GU 2019: The P-Value Debate: Lower Them or Leave Them?

ASCO GU 2019: Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery – Surgeon Perspective

ASCO GU 2019: Practice Makes Perfect: Should All Testicular Cancer Cases Be Discussed with High-Volume Centers?

ASCO GU 2019: Penile Carcinoma Regional Lymph Node Involvement: Radiation Versus Surgery – Radiation Oncology Perspective

ASCO GU 2019: MicroRNA 371 As a Biomarker: Is It a Breakthrough?

ASCO GU 2019: Results of a 50 Patient Single-Centre Phase II Prospective Trial of Lutetium-177 PSMA-617 Theranostics in mCRPC

ASCO GU 2019: Oligometastatic Disease: Tumor Board - Medical Oncologist Perspective by Silke Gillessen, MD

ASCO GU 2019: A Phase II Trial in Progress: Pamiparib, an Investigational PARP Inhibitor, in Patients with mCRPC and a Circulating Tumor Cell Homologous Recombination Deficiency Phenotype or BRCA Defects

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Radiation Oncologist Perspective by Gert de Meerleer, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board, A Radiation Oncologist Perspective by Bridget Koontz, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Medical Oncologist Perspective by Michael Morris, MD

ASCO GU 2019: Oligometastatic Disease: Tumor Board - A Urologic Oncologist Perspective by Edward Schaeffer, MD

ASCO GU 2019: ATLAS: A Phase II Open-Label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2019: Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence

ASCO GU 2019: Updated Results of Keynote 057: Pembrolizumab for Patients with High-risk Nonmuscle Invasive Bladder Cancer Unresponsive to BCG

1
2
3
4
5
6
7
8